| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3108 | Human TROP2-CT26 Stable Cell Line | 2 vials | $4950 | Order |
| Catalog Number | C3108 |
|---|---|
| Cell Line Name | Human TROP2-CT26 stable cell line |
| Accession Number | NM_002353.3 |
| Host Cell | CT26 |
| Quantity | Two vials of frozen cells (2x106 per vial) |
| Culture Medium | RPMI with 10% FBS, 10 µg/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen |
| Product Datasheet: | Download PDF |
Detection of human TROP2 expression on human TROP2-CT26 stable cells (A) and CT26 stable cells (B) using PE-anti-human-TROP2 Ab (BioLegend, #363803).
TROP2, also known as TACSTD2 (tumor-associated calcium signal transducer 2), is a transmembrane glycoprotein that plays a significant role in cell adhesion, proliferation, and signal transduction. It acts as a cell surface receptor and is involved in diverse cellular processes such as cell growth, differentiation, and migration. TROP2 is also associated with epithelial-mesenchymal transition (EMT), a process involved in embryonic development and tumor metastasis. In terms of tissue expression, TROP2 is predominantly found in epithelial tissues. It is expressed in various organs, including the lung, breast, colon, pancreas, prostate, and ovary. TROP2 expression is particularly high in epithelial cells lining the gastrointestinal tract and the ducts of different glands. TROP2 has gained significant attention in the field of cancer research due to its dysregulation in various malignancies. Elevated TROP2 expression has been observed in several cancer types and has been associated with tumor progression, invasion, and poor prognosis. As a result, TROP2 has emerged as a potential therapeutic target for anticancer interventions.
Cubas R, Li M, Chen C, Yao Q. Biochim Biophys Acta. 1796:309-314. 2009.
Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Mol Cancer Ther. 7:280-285. 2008.